Nicotinamide suppresses hyperphosphatemia in hemodialysis patients.

摘要: Nicotinamide suppresses hyperphosphatemia in hemodialysis patients. Background The use of calcium- or aluminum-based phosphate binders against is limited by the adverse effects hypercalcemia aluminum toxicity long-term hemodialysis. Because nicotinamide an inhibitor sodium-dependent cotransport rat renal tubule and small intestine, we examined whether reduces serum levels phosphorus intact parathyroid hormone (iPTH) patients undergoing Methods Sixty-five with a level more than 6.0mg/dL after 2-week washout calcium carbonate were enrolled this study. was administered for 12weeks. starting dose 500mg/day, increased 250mg/day every 2weeks until well controlled at less 6.0mg/dL. A posttreatment period followed cessation nicotinamide. Blood samples collected week measurement calcium, phosphorus, lipids, iPTH, blood adenine dinucleotide (NAD). Results mean 1080mg/day. NAD concentration from 9.3 ± 1.9nmol/10 5 erythrocytes before treatment to 13.2 5.3nmol/10 ( P Conclusion may provide alternative controlling hyperparathyroidism without inducing